TRT(SH:600085) Zhong Guo Zhi Liang Xin Wen Wang·2025-12-22 05:18Core Viewpoint - The clinical study of Angong Jiangya Wan, conducted by a team from Capital Medical University and eight medical institutions, provides new evidence for the treatment of secondary hypertension with liver yang hyperactivity, highlighting its clinical value and application prospects [1]. Group 1: Blood Pressure Control Effect - The study, a multi-center, randomized, double-blind, placebo-controlled trial, included 240 patients and demonstrated a significant reduction in systolic/diastolic blood pressure by 15.58±10.16/9.72±7.41 mmHg, which is clinically meaningful for secondary hypertension patients [1]. - The blood pressure control rate reached 31.86%, validating the efficacy of Angong Jiangya Wan as an adjunct treatment for patients whose blood pressure remains uncontrolled after standard therapy [1]. Group 2: Symptom Improvement and Synergistic Effect - Angong Jiangya Wan showed a clinical improvement rate of up to 94.62% for core symptoms such as dizziness and headache, significantly outperforming the control group in both TCM syndrome scoring and quality of life scoring [2]. - The drug demonstrated stable synergistic effects when used in combination with mainstream treatment regimens, such as CCB+ARB and CCB+β-blockers, indicating its compatibility without the need to alter existing treatment frameworks [2]. Group 3: Safety and Academic Significance - No adverse events were reported during the trial, confirming the safety of Angong Jiangya Wan in combination therapy, which is crucial for long-term hypertension management [2]. - The study employs an internationally recognized evidence-based medicine approach to validate the efficacy of traditional Chinese medicine, providing a model for the modernization of TCM and the integration of Chinese and Western medicine in hypertension treatment [3].